Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Recruiting · NCT07594093 · Interventional (participants receive a specific treatment) · Lead sponsor: Regeneron Pharmaceuticals
View the official record on ClinicalTrials.gov →Interventions studied
PlaceboREGN20934
What this trial is about
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
Who can take part
Age range
18 Years to 65 Years
Sex
All (male and female)
Healthy volunteers
Yes - healthy volunteers may be accepted
Phase
Phase 1
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Has a Body Mass Index (BMI) 25 to 35 kg/m\^2
- Females must be of non-childbearing potential
- Key
Exclusion criteria
- A self-reported change of body weight \>5 kg within approximately 90 days of visit 2
- History of type 1 or type 2 diabetes
- History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol
- Note: Other protocol defined inclusion/exclusion criteria apply
Where it is running
1 location listed across 1 US state.
- California Clinical Trials Medical Group - Glendale, California, United States